2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T46a,A total of 160 omalizumab-naive and omalizumab-incomplete responders were randomized (mean [SD] age, 44.1 [13.4] years; 112 [70.0%] female). The primary analysis population included only the 143 omalizumab-naive patients. Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, -9.21 vs -5.77; difference, -3.44 [95% CI, -6.25 to -0.62]; P = .02) and UAS7 (LS mean, -16.89 vs -10.14; difference, -6.75 [95% CI, -12.23 to -1.26]; P = .02). In addition, improvements in weekly Hives Severity Score (HSS7) and weekly Angioedema Activity Score (AAS7) were observed. Improvements in ISS7, UAS7, HSS7, and AAS7 were observed as early as week 1. CSU-related biomarkers, including soluble Mas-related G protein-coupled receptor X2, immunoglobulin (Ig)-G antithyroid peroxidase, IgG anti-Fc-ε receptor 1, and interleukin-31, were reduced compared to placebo at week 12. Rilzabrutinib demonstrated a favorable risk-benefit profile; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.31:Tbc6,Chronic spontaneous urticaria (CSU) is a skin disease driven mainly by the activation of cutaneous mast cells through various mechanisms. Bruton tyrosine kinase (BTK), expressed in B cells and mast cells, plays a critical role in multiple immune-mediated disease processes. To determine the efficacy and risk profile of rilzabrutinib (SAR444671), an oral, reversible, covalent, next-generation BTK inhibitor, in treating patients with CSU. The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension. The trial was conducted from November 24, 2021, through April 23, 2024. Fifty-one centers enrolled and randomized participants across 12 countries in Asia, Europe, North America, and South America. The trial participants included adults aged 18 to 80 years with moderate to severe CSU (weekly Urticaria Activity Score [UAS7] of 16 or more; weekly Itch Severity Score [ISS7] of 8 or more) not adequately controlled with H1-antihistamine treatment. Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo. The primary end point was change from baseline at week 12 in ISS7 (for US and US reference countries) or UAS7 (for non-US reference countries). A total of 160 omalizumab-naive and omalizumab-incomplete responders were randomized (mean [SD] age, 44.1 [13.4] years; 112 [70.0%] female). The primary analysis population included only the 143 omalizumab-naive patients. Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, -9.21 vs -5.77; difference, -3.44 [95% CI, -6.25 to -0.62]; P = .02) and UAS7 (LS mean, -16.89 vs -10.14; difference, -6.75 [95% CI, -12.23 to -1.26]; P = .02). In addition, improvements in weekly Hives Severity Score (HSS7) and weekly Angioedema Activity Score (AAS7) were observed. Improvements in ISS7, UAS7, HSS7, and AAS7 were observed as early as week 1. CSU-related biomarkers, including soluble Mas-related G protein-coupled receptor X2, immunoglobulin (Ig)-G antithyroid peroxidase, IgG anti-Fc-ε receptor 1, and interleukin-31, were reduced compared to placebo at week 12. Rilzabrutinib demonstrated a favorable risk-benefit profile; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache. The results of the RILECSU randomized clinical trial demonstrated efficacy and rapid onset of action of rilzabrutinib, 1200 mg/d, over 12 weeks, in addition to an acceptable adverse event profile. Together, these data support the use of rilzabrutinib in treating patients with moderate to severe CSU refractory to H1-antihistamines. Further research is needed to determine long-term efficacy and potential harms. ClinicalTrials.gov Identifier: NCT05107115.32:Tf48,ImportanceChronic spontaneous urticaria (CSU) is a skin disease driven mainly by the activation of cutaneous mast cells through various mechanisms. Bruton tyrosine kinase (BTK), expressed in B cells and mast cells, plays a critical role in multiple immune-mediated disease processes.ObjectiveTo determine the efficacy and risk profile of rilzabrutinib (SAR444671), an oral, reversible, covalent, next-generation BTK inhibitor, in treating patients with CSU.Design, Setting, and ParticipantsThe Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension. The trial was conducted from November 24, 2021, through April 23, 2024. Fifty-one centers enrolled and randomized participants across 12 countries in Asia, Europe, North America, and South America. The trial participants included adults aged 18 to 80 years with moderate to severe CSU (weekly Urticaria Activity Score [UAS7] of 16 or more; weekly Itch Severity Score [ISS7] of 8 or more) not adequately controlled with H1-antihistamine treatment.InterventionsPatients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.Main OutcomesThe primary end point was change from baseline at week 12 in ISS7 (for US and US reference countries) or UAS7 (for non-US reference countries).ResultsA total of 160 omalizumab-naive and omalizumab-incomplete responders were randomized (mean [SD] age, 44.1 [13.4] years; 112 [70.0%] female). The primary analysis population included only the 143 omalizumab-naive patients. Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P = .02). In addition, improvements in weekly Hives Severity Score (HSS7) and weekly Angioedema Activity Score (AAS7) were observed. Improvements in ISS7, UAS7, HSS7, and AAS7 were observed as early as week 1. CSU-related biomarkers, including soluble Mas-related G protein–coupled receptor X2, immunoglobulin (Ig)-G antithyroid peroxidase, IgG anti-Fc-ε receptor 1, and interleukin-31, were reduced compared to placebo at week 12. Rilzabrutinib demonstrated a favorable risk-benefit profile; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.Conclusions and RelevanceThe results of the RILECSU randomized clinical trial demonstrated efficacy and rapid onset of action of rilzabrutinib, 1200 mg/d, over 12 weeks, in addition to an acceptable adverse event profile. Together, these data support the use of rilzabrutinib in treating patients with moderate to severe CSU refractory to H1-antihistamines. Further research is needed to determine long-term efficacy and potential harms.Trial RegistrationClinicalTrials.gov Identifier: NCT0510711525:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"rilzabrutinib: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on rilzabrutinib (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/rilzabrutinib\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"rilzabrutinib\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/rilzabrutinib\"}]}}"}}]],["$","$L2f",null,{"title":"rilzabrutinib: Research & Clinical Takeaways","description":"Explore research on rilzabrutinib (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1001/jamadermatol.2025.0733","pmid":"40266575","title":"Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-04-23T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.0733","source_score":49,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-05-27","doi":"10.1001/jamadermatol.2025.0733","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"49","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.0733","title":"Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"40266575","conclusions":"","publication_date":"2025-04-23T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.0733","URL":"https://doi.org/10.1001/jamadermatol.2025.0733","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2833141/jamadermatology_gimnezarnau_2025_oi_250013_1752181147.17467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"679","type":"journal-article","issue":"7","score":1,"title":["Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria"],"author":[{"given":"Ana","family":"Giménez-Arnau","sequence":"first","affiliation":[{"name":"Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain"}]},{"given":"Silvia","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"SC Dermatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy"}]},{"given":"Moshe","family":"Ben-Shoshan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montréal, Quebec, Canada"}]},{"given":"Vincent","family":"Mikol","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}]},{"given":"Laurence","family":"Lucats","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}]},{"given":"Iris","family":"Sun","sequence":"additional","affiliation":[{"name":"Sanofi, Beijing, China"}]},{"given":"Leda","family":"Mannent","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}]},{"given":"Jessica","family":"Gereige","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts"}]}],"issued":{"date-parts":[[2025,7,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-04-23T11:30:54Z","timestamp":1745407854000,"date-parts":[[2025,4,23]]},"indexed":{"date-time":"2025-08-30T16:29:58Z","timestamp":1756571398337,"date-parts":[[2025,8,30]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2833141"}},"subtitle":["The RILECSU Phase 2 Randomized Clinical Trial"],"deposited":{"date-time":"2025-07-16T15:00:39Z","timestamp":1752678039000,"date-parts":[[2025,7,16]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,7,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/all.15603","key":"doi250013r1","year":"2023","issue":"2","author":"Kaplan","volume":"78","first-page":"389","unstructured":null,"article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-023-00955-7","key":"doi250013r2","year":"2023","issue":"8","author":"Armstrong","volume":"13","first-page":"1629","unstructured":null,"article-title":"Chronic spontaneous urticaria: how to measure it and the need to define treatment success.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41572-022-00389-z","key":"doi250013r3","year":"2022","issue":"1","author":"Kolkhir","volume":"8","first-page":"61","unstructured":null,"article-title":"Urticaria.","journal-title":"Nat Rev Dis Primers","doi-asserted-by":"publisher"},{"DOI":"10.2500/aap.2023.44.230011","key":"doi250013r4","year":"2023","issue":"3","author":"Can","volume":"44","first-page":"179","unstructured":null,"article-title":"Common but neglected problem in chronic spontaneous urticaria: sleep disturbance.","journal-title":"Allergy Asthma Proc","doi-asserted-by":"publisher"},{"DOI":"10.1186/s40360-023-00665-y","key":"doi250013r5","year":"2023","issue":"1","author":"Xiao","volume":"24","first-page":"23","unstructured":null,"article-title":"The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials.","journal-title":"BMC Pharmacol Toxicol","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15090","key":"doi250013r6","year":"2022","issue":"3","author":"Zuberbier","volume":"77","first-page":"734","unstructured":null,"article-title":"The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15261","key":"doi250013r7","year":"2022","issue":"8","author":"Mendes-Bastos","volume":"77","first-page":"2355","unstructured":null,"article-title":"Bruton’s tyrosine kinase inhibition—an emerging therapeutic strategy in immune-mediated dermatological conditions.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.3390/molecules28052400","key":"doi250013r8","year":"2023","issue":"5","author":"Rozkiewicz","volume":"28","first-page":"2400","unstructured":null,"article-title":"Bruton’s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials.","journal-title":"Molecules","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.08.027","key":"doi250013r9","year":"2022","issue":"6","author":"Maurer","volume":"150","first-page":"1498","unstructured":null,"article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40521-021-00286-y","key":"doi250013r10","year":"2021","issue":"3","author":"Dispenza","volume":"8","first-page":"261","unstructured":null,"article-title":"The use of Bruton’s tyrosine kinase inhibitors to treat allergic disorders.","journal-title":"Curr Treat Options Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2024.03.002","key":"doi250013r11","year":"2024","issue":"1","author":"Lin","volume":"133","first-page":"33","unstructured":null,"article-title":"Bruton’s tyrosine kinase inhibition for the treatment of allergic disorders.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.10.007","key":"doi250013r12","year":"2024","issue":"2","author":"Jain","volume":"153","first-page":"479","unstructured":null,"article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/cts.13524","key":"doi250013r13","year":"2023","issue":"7","author":"Ucpinar","volume":"16","first-page":"1210","unstructured":null,"article-title":"Rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase inhibitor: absorption, metabolism, excretion, and absolute bioavailability in healthy participants.","journal-title":"Clin Transl Sci","doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.2001130","key":"doi250013r14","year":"2021","issue":"7","author":"Langrish","volume":"206","first-page":"1454","unstructured":null,"article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease.","journal-title":"J Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-021-01537-w","key":"doi250013r15","year":"2021","issue":"11","author":"Metz","volume":"27","first-page":"1961","unstructured":null,"article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.4168/aair.2021.13.3.498","key":"doi250013r16","year":"2021","issue":"3","author":"Cao","volume":"13","first-page":"498","unstructured":null,"article-title":"Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria.","journal-title":"Allergy Asthma Immunol Res","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm12185957","key":"doi250013r17","year":"2023","issue":"18","author":"Dobrican-Baru?a","volume":"12","first-page":"5957","unstructured":null,"article-title":"IL-31-pruritus interleukin: serum values and clinical impact in chronic spontaneous urticaria—a Romanian retrospective study.","journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2021.639097","key":"doi250013r18","year":"2021","issue":null,"author":"Nemmer","volume":"8","first-page":null,"unstructured":null,"article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues.","journal-title":"Front Med (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20431","key":"doi250013r19","year":"2021","issue":"4","author":"Murrell","volume":"185","first-page":"745","unstructured":null,"article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2110297","key":"doi250013r20","year":"2022","issue":"15","author":"Kuter","volume":"386","first-page":"1421","unstructured":null,"article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm11206139","key":"doi250013r21","year":"2022","issue":"20","author":"Garg","volume":"11","first-page":"6139","unstructured":null,"article-title":"Bruton’s tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis.","journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2023.10.019","key":"doi250013r22","year":"2023","issue":"5","author":"Saini","volume":"131","first-page":"S230","unstructured":null,"article-title":"Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.11.873","key":"doi250013r23","year":"2024","issue":"2","author":"Maurer","volume":"153","first-page":"AB366","unstructured":null,"article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a phase 2 trial.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,7,1]]},"reference-count":23,"published-online":null,"references-count":23,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2025.0733","is_oa":true,"title":"Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-04-23","best_oa_location":{"url":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2833141/jamadermatology_gimnezarnau_2025_oi_250013_1744814472.89308.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2833141/jamadermatology_gimnezarnau_2025_oi_250013_1744814472.89308.pdf","url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2025.0733"}}},"created_at":"2025-09-19T18:59:16.498Z","updated_at":"2025-09-19T18:59:43.302Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"condition","value":"Chronic Spontaneous Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"generic","value":"rilzabrutinib","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"modality","value":"BTK Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"sample_size","value":"n=160","value_numeric":160},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"warning","value":"Dual primary end point (ISS7 vs UAS7 by country) and a short 12-week blinded period; the open-label extension may introduce bias for longer-term outcomes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"warning","value":"Only the 1200 mg/d dose showed significant benefit vs placebo in the data provided; results for lower doses were not detailed.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.0733","tag_type":"warning","value":"Primary analysis was limited to omalizumab-naive patients (n=143), not all randomized participants.","value_numeric":null}],"summaries":{"what_studied":"A 52-week phase 2 randomized, double-blind, placebo-controlled, dose-ranging trial tested oral rilzabrutinib (400 mg qPM, 800 mg/d, or 1200 mg/d) vs placebo for 12 weeks in adults (18-80 years) with moderate to severe antihistamine-refractory chronic spontaneous urticaria across 12 countries; the primary analysis used omalizumab-naive patients (n=143). The primary end point was change from baseline at week 12 in ISS7 (US/reference) or UAS7 (non-US).","key_result":"At week 12, rilzabrutinib 1200 mg/d improved ISS7 vs placebo (LS mean change -9.21 vs -5.77; difference -3.44; 95% CI -6.25 to -0.62; P=.02) and UAS7 vs placebo (LS mean change -16.89 vs -10.14; difference -6.75; 95% CI -12.23 to -1.26; P=.02) in omalizumab-naive patients. Improvements in HSS7 and AAS7 occurred as early as week 1; diarrhea, nausea, and headache were more frequent with rilzabrutinib than placebo.","limitations":"Primary analysis excluded omalizumab-incomplete responders and focused on omalizumab-naive patients (n=143). The blinded period was only 12 weeks with a 40-week open-label extension, limiting long-term efficacy and safety inferences.","practice_takeaway":"For H1-antihistamine–refractory CSU, rilzabrutinib 1200 mg/d reduced itch and hive activity over 12 weeks vs placebo with early onset and mainly gastrointestinal and headache adverse events. Use is supported by these phase 2 results, but longer-term benefits and harms remain uncertain."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"rilzabrutinib"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"rilzabrutinib"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"rilzabrutinib"}}}]]

Papers